Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. more
Time Frame | MRK | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.56% | -0.78% | -1.28% |
1-Month Return | -3.01% | 0.89% | 1.37% |
3-Month Return | 0.59% | 6.29% | 12.01% |
6-Month Return | 7.09% | 6.29% | 15.36% |
1-Year Return | 21.87% | 12.68% | 23.24% |
3-Year Return | 78.58% | 21.13% | 36.17% |
5-Year Return | 88.51% | 74.73% | 101.78% |
10-Year Return | 208.29% | 182.71% | 236.91% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 46.84B | 47.99B | 48.70B | 59.28B | 59.87B | [{"date":"2019-12-31","value":78.23,"profit":true},{"date":"2020-12-31","value":80.16,"profit":true},{"date":"2021-12-31","value":81.35,"profit":true},{"date":"2022-12-31","value":99.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 14.11B | 15.48B | 13.63B | 17.41B | 15.98B | [{"date":"2019-12-31","value":81.05,"profit":true},{"date":"2020-12-31","value":88.94,"profit":true},{"date":"2021-12-31","value":78.26,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.76,"profit":true}] |
Gross Profit | 32.73B | 32.51B | 35.08B | 41.87B | 43.89B | [{"date":"2019-12-31","value":74.56,"profit":true},{"date":"2020-12-31","value":74.06,"profit":true},{"date":"2021-12-31","value":79.92,"profit":true},{"date":"2022-12-31","value":95.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 69.87% | 67.74% | 72.02% | 70.63% | 73.31% | [{"date":"2019-12-31","value":95.3,"profit":true},{"date":"2020-12-31","value":92.39,"profit":true},{"date":"2021-12-31","value":98.24,"profit":true},{"date":"2022-12-31","value":96.34,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 20.49B | 24.03B | 21.88B | 23.59B | 40.91B | [{"date":"2019-12-31","value":50.08,"profit":true},{"date":"2020-12-31","value":58.73,"profit":true},{"date":"2021-12-31","value":53.48,"profit":true},{"date":"2022-12-31","value":57.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 9.23B | 5.44B | 10.65B | 14.71B | 2.98B | [{"date":"2019-12-31","value":62.73,"profit":true},{"date":"2020-12-31","value":36.95,"profit":true},{"date":"2021-12-31","value":72.37,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":20.27,"profit":true}] |
Total Non-Operating Income/Expense | 1.62B | 2.58B | 2.46B | 929.00M | (1.77B) | [{"date":"2019-12-31","value":62.64,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":95.35,"profit":true},{"date":"2022-12-31","value":35.97,"profit":true},{"date":"2023-12-31","value":-68.68,"profit":false}] |
Pre-Tax Income | 11.46B | 8.79B | 13.88B | 16.44B | 1.89B | [{"date":"2019-12-31","value":69.72,"profit":true},{"date":"2020-12-31","value":53.46,"profit":true},{"date":"2021-12-31","value":84.4,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":11.49,"profit":true}] |
Income Taxes | 1.69B | 1.71B | 1.52B | 1.92B | 1.51B | [{"date":"2019-12-31","value":87.96,"profit":true},{"date":"2020-12-31","value":89.1,"profit":true},{"date":"2021-12-31","value":79.3,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":78.83,"profit":true}] |
Income After Taxes | 9.78B | 7.08B | 12.36B | 14.53B | 377.00M | [{"date":"2019-12-31","value":67.31,"profit":true},{"date":"2020-12-31","value":48.75,"profit":true},{"date":"2021-12-31","value":85.08,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":2.6,"profit":true}] |
Income From Continuous Operations | 9.78B | 7.08B | 12.36B | 14.53B | 4.62B | [{"date":"2019-12-31","value":67.31,"profit":true},{"date":"2020-12-31","value":48.75,"profit":true},{"date":"2021-12-31","value":85.08,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":31.81,"profit":true}] |
Income From Discontinued Operations | 704.00M | 704.00M | 704.00M | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 9.84B | 7.07B | 13.05B | 14.52B | 365.00M | [{"date":"2019-12-31","value":67.79,"profit":true},{"date":"2020-12-31","value":48.67,"profit":true},{"date":"2021-12-31","value":89.88,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":2.51,"profit":true}] |
EPS (Diluted) | 5.19 | 5.93 | 6.26 | 7.48 | 1.50 | [{"date":"2019-12-31","value":69.39,"profit":true},{"date":"2020-12-31","value":79.28,"profit":true},{"date":"2021-12-31","value":83.69,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":20.05,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
MRK | |
---|---|
Current Ratio | 1.25 |
Quick Ratio | 0.99 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MRK | |
---|---|
ROA (LTM) | 10.26% |
ROE (LTM) | 5.31% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MRK | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.62 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.38 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 2.62 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MRK | |
---|---|
Trailing PE | 139.61 |
Forward PE | 14.68 |
P/S (TTM) | 5.30 |
P/B | 8.48 |
Price/FCF | NM |
EV/R | 5.76 |
EV/Ebitda | 50.16 |
PEG | NM |
BeiGene appoints Merck veteran Aaron Rosenberg as CFO, bolstering its position as a top 15 global oncology innovator. Learn how this strategic move supports BeiGene''s growth and leadership in cancer treatments.
… in-house formulation knowledge, Merck designs robust custom CCM for … processes. “This investment further expands Merck ’s footprint and capabilities in … lines, bioreactors, filters, resins, chromatographic, pharmaceutical raw materials, and excipients. Its …
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Merck said it plans to acquire Unity-SC, a provider of metrology and inspection instrumentation for the semiconductor industry. The transaction amount includes…
Merck has beaten back an appeal by nearly 1,200 plaintiffs who claimed their cases were improperly dismissed by the federal judge overseeing mass torts litigation over its Zostavax shingles vaccine.
Brianne Gardner, senior wealth manager at Velocity Investment Partners, Raymond James, discusses his past picks: Canadian Natural Resources, Tourmaline Oil, and Merck & Co.
Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck’s (NYSE: MRK ) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year. And even back in 2018, its fourth year on the market, the drug was responsible for putting $7.2 billion in Merck’s coffers. Many new types of cancer treatments are being developed, including personalized cancer vaccines, and precision oncology treatments. But very few treatments have the potential to be the next Keytruda. In this column on cancer treatment stocks, I will identify two companies with drugs that I think could fit the bill. I will also profile a company that has developed a blood test which successfully detects many types of the disease in the early stages. By doing so, it can save millions of lives. Grail ( GRAL ) Source: JHVEPhoto / Shutterstock.com Grail’s (NASDAQ: GRAL ) Galleri blood test can determine whether individuals have over 50 types of cancer.
How one employee''s upbringing and career journey have motivated her to fight inequities around the world NORTHAMPTON, MA / ACCESSWIRE / July 16, 2024 / For Priya Agrawal, health equity has been a l…
How one employee''s upbringing and career journey have motivated her to fight inequities around the world NORTHAMPTON, MA / ACCESSWIRE / July 16, 2024 / For Priya Agrawal, health equity has been a lifelong concern and a guiding principle in the work … Jetzt den vollständigen Artikel lesen
While the last two major global pandemics were more than 100 years apart, a few international agencies warn of the increased potential for more frequent pandemics. This is admittedly a concerning and uncomfortable thought, considering the severe societal damage that occurred as a result of the Covid-19 pandemic. That being said, the opportunity always exists for biotech stocks during times of health crisis. Especially vaccines and prophylactic measures, which could turn lucrative for investors, due to investing in early on a company whose products become critical to a worldwide solution. To determine the potential of these companies’ treatments, we will look at their scalability, and the disease they’re intended to address. As such here are three biotech stocks to watch for the future of global health. Moderna (MRNA) Source: Carlos l Vives / Shutterstock.com Moderna (NASDAQ: MRNA ) is the vaccine producer focused on using the mRNA technology. Yet, what is exceptionally exciting about this technology is how readily it can be applied to other types of respiratory viruses beyond the one that caused the Covid-19 pandemic.
Merck & Company Inc (MRK) share price today is $125.77
Yes, Indians can buy shares of Merck & Company Inc (MRK) on Vested. To buy Merck & Company Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MRK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Merck & Company Inc (MRK) via the Vested app. You can start investing in Merck & Company Inc (MRK) with a minimum investment of $1.
You can invest in shares of Merck & Company Inc (MRK) via Vested in three simple steps:
The 52-week high price of Merck & Company Inc (MRK) is $134.63. The 52-week low price of Merck & Company Inc (MRK) is $97.23.
The price-to-earnings (P/E) ratio of Merck & Company Inc (MRK) is 138.82
The price-to-book (P/B) ratio of Merck & Company Inc (MRK) is 8.48
The dividend yield of Merck & Company Inc (MRK) is 2.48%
The market capitalization of Merck & Company Inc (MRK) is $318.55B
The stock symbol (or ticker) of Merck & Company Inc is MRK